Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Evolving treatment paradigms in sickle cell disease.

Jagadeeswaran R, Rivers A.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):440-446. doi: 10.1182/asheducation-2017.1.440. Review.

2.

Simultaneous polymerization and adhesion under hypoxia in sickle cell disease.

Papageorgiou DP, Abidi SZ, Chang HY, Li X, Kato GJ, Karniadakis GE, Suresh S, Dao M.

Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):9473-9478. doi: 10.1073/pnas.1807405115. Epub 2018 Sep 6.

3.

Thrombosis and sickle cell disease.

De Franceschi L, Cappellini MD, Olivieri O.

Semin Thromb Hemost. 2011 Apr;37(3):226-36. doi: 10.1055/s-0031-1273087. Epub 2011 Mar 31. Review.

PMID:
21455857
4.

New insights into the pathophysiology and development of novel therapies for sickle cell disease.

Moerdler S, Manwani D.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):493-506. doi: 10.1182/asheducation-2018.1.493. Review.

PMID:
30504350
5.
6.
7.

Sickle cell disease: role of reactive oxygen and nitrogen metabolites.

Wood KC, Granger DN.

Clin Exp Pharmacol Physiol. 2007 Sep;34(9):926-32. Review.

PMID:
17645642
8.

Sickle red cell microrheology and sickle blood rheology.

Ballas SK, Mohandas N.

Microcirculation. 2004 Mar;11(2):209-25. Review.

PMID:
15280093
9.

2015 Clinical trials update in sickle cell anemia.

Archer N, Galacteros F, Brugnara C.

Am J Hematol. 2015 Oct;90(10):934-50. doi: 10.1002/ajh.24116. Review.

10.

Sickle red cell-endothelium interactions.

Kaul DK, Finnegan E, Barabino GA.

Microcirculation. 2009 Jan;16(1):97-111. doi: 10.1080/10739680802279394. Review.

11.

Sickle cell vasoocclusion: heterotypic, multicellular aggregations driven by leukocyte adhesion.

Frenette PS.

Microcirculation. 2004 Mar;11(2):167-77. Review.

PMID:
15280090
12.

Pathophysiological insights in sickle cell disease.

Odièvre MH, Verger E, Silva-Pinto AC, Elion J.

Indian J Med Res. 2011 Oct;134:532-7. Review.

13.

Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease.

Jagadeeswaran R, Vazquez BA, Thiruppathi M, Ganesh BB, Ibanez V, Cui S, Engel JD, Diamond AM, Molokie RE, DeSimone J, Lavelle D, Rivers A.

Exp Hematol. 2017 Jun;50:46-52. doi: 10.1016/j.exphem.2017.02.003. Epub 2017 Feb 24.

15.

Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease.

Maier-Redelsperger M, Noguchi CT, de Montalembert M, Rodgers GP, Schechter AN, Gourbil A, Blanchard D, Jais JP, Ducrocq R, Peltier JY, et al.

Blood. 1994 Nov 1;84(9):3182-8.

16.

Modulation of Sickle Red Blood Cell Adhesion and its Associated Changes in Biomarkers by Sulfated Nonanticoagulant Heparin Derivative.

Alshaiban A, Muralidharan-Chari V, Nepo A, Mousa SA.

Clin Appl Thromb Hemost. 2016 Apr;22(3):230-8. doi: 10.1177/1076029614565880. Epub 2015 Jan 19.

PMID:
25601897
17.

Role of oxidative stress in the pathogenesis of sickle cell disease.

Chirico EN, Pialoux V.

IUBMB Life. 2012 Jan;64(1):72-80. doi: 10.1002/iub.584. Epub 2011 Nov 30. Review.

18.

New insights provided by a comparison of impaired deformability with erythrocyte oxidative stress for sickle cell disease.

Barodka VM, Nagababu E, Mohanty JG, Nyhan D, Berkowitz DE, Rifkind JM, Strouse JJ.

Blood Cells Mol Dis. 2014 Apr;52(4):230-5. doi: 10.1016/j.bcmd.2013.10.004. Epub 2013 Nov 15.

PMID:
24246527
19.

The delay time in sickle cell disease after 40 years: A paradigm assessed.

Ferrone FA.

Am J Hematol. 2015 May;90(5):438-45. doi: 10.1002/ajh.23958. Epub 2015 Feb 25. Review.

20.

Sickle cell biomechanics.

Barabino GA, Platt MO, Kaul DK.

Annu Rev Biomed Eng. 2010 Aug 15;12:345-67. doi: 10.1146/annurev-bioeng-070909-105339. Review.

PMID:
20455701

Supplemental Content

Support Center